Male Hypogonadism Market Size, Share, Trends, Growth and Forecast 2032

Male Hypogonadism Market Insights

Zion Market Research has published a report on the global Male Hypogonadism Market, estimating its value at USD 3.63 Billion in 2023, with projections indicating that it will reach USD 5.83 Billion by 2032. The market is expected to expand at a compound annual growth rate (CAGR) of 5.4% over the forecast period 2024-2032.

The report explores the factors fueling market growth, the hitches that could hamper this expansion, and the opportunities that may arise in the Male Hypogonadism industry. Additionally, it offers a detailed analysis of how these elements will affect market demand dynamics and market performance throughout the forecast period.

Request Free Sample

Global Male Hypogonadism Market: Overview

Male hypogonadism is a medical condition, wherein the testes fail to generate enough testosterone which leads to incomplete development or delayed puberty. The condition is related to the development of breast tissues, impaired development of muscle mass, lack of deepening of the voice, and impaired body hair growth.

Global Male Hypogonadism Market: Segmentation

The male hypogonadism market is globally segmented into therapy, drug delivery, and type.

On the basis of therapy, the market is segregated into testosterone replacement therapy and gonadotropin-releasing hormone therapy.

The gonadotropin-releasing hormones therapy is further sub-divided into luteinizing hormone (LH), human chorionic gonadotropin (hCG), follicle-stimulating hormone (FSH), and gonadotropin-releasing hormone (GnRH).

Based on the drug delivery, the market is categorized into injectables, topical gels, transdermal patches, and others.

Depending on the type, the market is divided into Kallmann syndrome, Klinefelters syndrome, pituitary disorders, and others.

Request Free Sample

Global Male Hypogonadism Market: Growth Factors

The key factor that is driving the male hypogonadism market includes increasing cases of testosterone deficiency among men, increasing awareness among people about hypogonadism treatment owing to awareness drives that are organized by several governments across the world, and increasing infertility rates.

The high risk of hypogonadism among the aged population with obesity and diabetes and escalating cases of chronic disorders among the geriatrics are further boosting the market’s growth. On the other hand, factors such as the high side effects of testosterone products challenge the growth of the market.

The market players are focusing on research and development activities to introduce newer products with fewer or negligible side effects and better results. Technological advancements are anticipated to extend new opportunities to the market’s growth.

Male Hypogonadism Market: Report Scope

Global Male Hypogonadism Market: Regional Analysis

The male hypogonadism market can be segmented into regions such as North America, Asia-Pacific, Europe, Latin America, and the Middle East and Africa. North America dominates the market owing to the increase in the number of individuals that are suffering from the primary and secondary conditions of hypogonadism, and the rising awareness among the people about treatment. Other factors that contribute to this growth are the presence of unconventional healthcare infrastructure and the growing popularity of technologically advanced products which will offer new opportunities to the top market players in this market.

The region is strongly followed by Europe. Asia-Pacific region is expected to offer productive opportunities to this market owing to the modernization of the healthcare infrastructure in the developing economies of India and China and the growing awareness about the treatment for the condition. In the Asia Pacific, there is a rise in the number of people that suffer from hypogonadism and infertility rates coupled with the rise in the geriatric population base having obesity and diabetes are triggering the growth of the market.

Global Male Hypogonadism Market: Competitive Players

Some of the key market players that are involved in the male hypogonadism market include-

• Astrazeneca Plc.
• Merck & Co. Inc.
• Laboratories Genevrier
• Allergan Plc.
• Endo International Plc.
• Ferring
• AbbVie Inc.
• Eli Lilly and Company Ltd.
• Finox Biotech
• Teva Pharmaceutical Industries Ltd.
• Bayer AG
• IBSA Institut Biochimque.

The report segments the Global Male Hypogonadism market as follows:

Global Male Hypogonadism Market: Therapy Segment Analysis

• Testosterone replacement therapy
• Gonadotropin-releasing hormones therapy
  • Luteinizing Hormone (LH)
  • Human Chorionic Gonadotropin (hcg)
  • Follicle-Stimulating Hormone (FSH)
  • Gonadotropin-Releasing Hormone (GnRH)

Global Male Hypogonadism Market: Drug delivery Segment Analysis

• Injectables
• Topical gels
• Transdermal patches
• Others

Global Male Hypogonadism Market: Type Segment Analysis

• Kallmann syndrome
• Klinefelters syndrome
• Pituitary disorders
• Others

Global Male Hypogonadism Market: Regional Segment Analysis

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa